Please amend the claims as follows:

1. (Thrice Amended) A fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising: a podophyllotoxin selected from the group consisting of etoposide and teniposide, and tocoferol wherein said tocoferol consists of tocoferol covalently linked to a water-soluble polymer[[; with the proviso that free tocoferol is not present]].

2-3. (Cancelled without prejudice)

4. (Amended) The fluid pharmaceutical composition of claim 1 wherein the podophyllotoxin is etoposide.

5-6. (Cancelled without prejudice)

7. (Twice Amended) The fluid pharmaceutical composition of claim 1 wherein the water-soluble polymer is poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers polyacrylamides, polyglycerols, polyvinylalcohols, polyvinylpyrrolidones, polyvinylpyridine N-oxides, copolymers of vinylpyridine N-oxide and vinylpyridine, polyoxazolines, polyacroylmorpholines [[or derivatives thereof]].

8. (Twice Amended) The fluid pharmaceutical composition of claim 1 wherein the water-soluble polymer is a polypeptide [[or derivative thereof]].

9. (Amended) The fluid pharmaceutical composition of claim 1 wherein the water-soluble polymer further comprises a second hydrophobic group in addition to tocoferol.

10. (Thrice Amended) The fluid pharmaceutical composition of claim 1 wherein the tocoferol covalently linked to a water-soluble polymer is d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) or a derivative thereof formed by attaching a polymer on the tocoferol succinate portion or by attaching TPGS to the hydroxyl group of polyethylene glycol (PEG).

11. (Amended) The fluid pharmaceutical composition of claim 10 wherein the d-α-tocopheryl polyethylene glycol 1000 succinate is present at a concentration from about 0.02 wt % to about 20 wt %.

12. (Amended) The fluid pharmaceutical composition of claim 10 wherein the d-α-tocopheryl polyethylene glycol 1000 succinate is present at a concentration from about 0.02 wt % to about 10 wt %.

13. (Amended) The fluid pharmaceutical composition of claim 10 wherein the d-α-tocopheryl polyethylene glycol 1000 succinate is present at a concentration from about 4 wt % to about 10 wt %.

14. (Amended) The fluid pharmaceutical composition of claim 1 further comprising a targeting molecule.

15. (Amended) The fluid pharmaceutical composition of claim 14 wherein the targeting molecule comprises a targeting moiety and a lipophilic moiety.

16. (Amended) The fluid pharmaceutical composition of claim 15 wherein the targeting moiety is an antibody, hormone, carbohydrate, drug, cytokine, or interleukin.

17. (Amended) The fluid pharmaceutical composition of claim 15 wherein the targeting moiety is a peptide.

18. (Thrice Amended) A method of treating an animal comprising administering to the animal a fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising:

a podophyllotoxin selected from the group consisting of etoposide and teniposide, and tocoferol <u>wherein said tocoferol consists of tocoferol</u> covalently linked to a water-soluble polymer[[; with the proviso that free tocoferol is not present]].

19. (Thrice Amended) The method of claim 18 wherein the tocoferol covalently linked to a water-soluble polymer is d-α-tocopheryl polyethylene glycol 1000 succinate <u>(TPGS)</u> or a derivative thereof <u>formed by attaching a polymer on the tocoferol succinate portion or by attaching TPGS to the hydroxyl group of polyethylene glycol (PEG)</u>.

20. (Thrice Amended) A method of delivering a podophyllotoxin selected from the group consisting of etoposide and teniposide to a cell comprising administering to the cell a fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising:

a podophyllotoxin selected from the group consisting of etoposide and teniposide; and tocoferol wherein said tocoferol consists of tocoferol covalently linked to a water-soluble polymer[[; with the proviso that free tocoferol is not present]].

21. (Thrice Amended) A method of inhibiting cancer comprising administering to an animal having cancer a fluid pharmaceutical composition comprising an aqueous dispersion of micelles having an average diameter less than about 300 nm, said micelles comprising:

a podophyllotoxin selected from the group consisting of etoposide and teniposide; and tocoferol wherein said tocoferol consists of tocoferol covalently linked to a water-soluble polymer[[; with the proviso that free tocoferol is not present]].

22. (Entered) The fluid pharmaceutical composition of claim 1 wherein the micelles have an average diameter less than about 100 nm.

23. (Entered) The fluid pharmaceutical composition of claim 1 wherein the micelles have an average diameter less than about 50 nm.

24. (Entered) The fluid pharmaceutical composition of claim 1 wherein the micelles have an average diameter from about 3 nm to about 25 nm.

* * *